Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris currently has license or distribution arrangements in place for macimorelin in the U.S., Canada, Europe, the UK, and Israel and is actively seeking to expand its relationships for the potential regulatory approval and commercialization of macimorelin in other countries.
Macimorelin is currently marketed in the United States under the tradename Macrilen™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. Additionally, upon receipt of pricing and reimbursement approvals in the applicable country, Aeterna Zentaris expects that macimorelin will be marketed in Europe and the United Kingdom through a license agreement with Consilient Health Ltd under which Aeterna Zentaris will receive royalties on sales and other potential payments. In addition, under a commercialization and supply agreement entered into with MegaPharm Ltd., MegaPharm has been granted rights to seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority in exchange for certain royalty and other potential payments to Aeterna Zentaris.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is also actively pursuing potential business development opportunities for other non-strategic assets to monetize their value.